News & Analysis on Clinical Trial Services & Contract Research And Development
FSD Pharma, Raza Bokhari
By Ben Hargreaves
- Last updated on
FSD Pharma announces the transition of Raza Bokhari from interim CEO of the company to an official appointment as CEO of the company. In addition, he will hold the position of co-chairman of the board.
Bokhari held the position of interim CEO from February 2019, after originally joining the company as a director 11 months ago. Prior to joining FSD Pharma, Bokhari spent five years as chairman and CEO of Parkway Clinical Laboratories – a clinical reference laboratory performing diagnostic testing for those working in addiction and pain management.
FSD Pharma is itself looking into using cannabis-based medicine for the treatment of neurological disorders, such as chronic pain, fibromyalgia and irritable bowel syndrome.
Bokhari commented, “We aim to deliver sustainable, positive shareholder value in this groundbreaking, disruptive cannabinoid-based industry where we hope to have the potential to help alleviate pain and suffering for people around the world, through the use of medicinal grade cannabis and synthetic and biosynthetic cannabinoid pharmaceuticals.”